ask why

Latest research

Every new paper in 280 characters, with how strong the evidence is and what readers question about it. Free to read.

Infectious diseases · J Infect Dis · 2026-11-16

In a first-in-human trial, 51 healthy adults received single intravenous GB-0669 (100–2400 mg; n=36) or placebo (n=15). It was well tolerated with only mild adverse reactions, a half-life of 54 days, and dose-dependent virus neutralisation at 600 and 1200 mg.

RCTn = 51
Borriello et al. Randomized, Double-Blind, Placebo-Controlled First-in-Human Trial of a First-in-Class AI-Designed Monoclonal Antibody (GB-0669) Against the Conserved SARS-CoV-2 Spike S2 Stem Helix
Infectious diseases · Clin Infect Dis · 2026-10-28

In 833 adults aged ≥50, giving adjuvanted RSVPreF3 with an XBB.1.5 COVID-19 mRNA vaccine met non-inferiority for RSV-A and RSV-B titres vs sequential dosing but marginally missed it for SARS-CoV-2 (GMT ratio 1.31, 95% CI 1.13–1.51); safety was similar.

RCTn = 833
Bonten et al. Immunogenicity and Safety of Coadministration of AS01E-Adjuvanted Respiratory Syncytial Virus Prefusion F Protein Vaccine and a COVID-19 mRNA Vaccine in Adult s Aged ≥50 Years: A Phase 3, Randomized, Noninferiority Trial
Infectious diseases · J Infect Dis · 2026-10-15

Secondary analysis of the phase 3 CANOPY and a phase 1 trial: pemivibart raised day-28 measured neutralising antibody titres against XBB.1.5 over 55-fold in adults with and without significant immunocompromise; calculated titres correlated with measured ones (Spearman ≥0.73).

Secondary analysis
Narayan et al. Serum Virus-Neutralizing Antibody Titers in Clinical Trial Participants With and Without Immunocompromise Receiving Pemivibart, a Long-Acting Monoclonal Antibody for COVID-19
Infectious diseases · Vaccine · 2026-10-13

In 4000 Thai adults after a two-dose COVID-19 primary series, a single HXP-GPOVac booster met non-inferiority to VAXZEVRIA for day-14 neutralising antibodies (GMC ratio 0.83; seroconversion difference −2.35%); solicited AEs 43.7% vs 53.5%.

RCTn = 4,000
Prasert et al. Safety and immunogenicity of Thailand Government Pharmaceutical Organization (GPO) produced, COVID-19 vaccine, 10 μg HXP-GPOVac: A Phase III, double-blind, randomized trial in comparison with VAXZEVRIA
Infectious diseases · Clin Infect Dis · 2026-09-02

Pooled secondary analysis of 2 randomised trials (1,181,254 adults): electronic letter nudges increased influenza vaccination vs usual care (+2.79 percentage points), with a larger effect in the 73,830 immunosuppressed participants (+4.12 vs +2.70 points).

Meta-analysisn = 1,181,254
Reimer Jensen et al. Electronic Nudges to Increase Influenza Vaccination in Immunosuppressed Adults Across the Age Spectrum: A Pooled Analysis of 2 Nationwide Randomized Trials
Infectious diseases · Clin Infect Dis · 2026-08-24

IDSA guideline update gives 9 updated recommendations on nirmatrelvir/ritonavir, remdesivir and molnupiravir for adults with mild to moderate COVID-19, based on a systematic review and GRADE, with an algorithm for choosing an antiviral.

Guideline
Shumaker et al. 2025 Clinical Practice Guideline Update by the Infectious Diseases Society of America on the Treatment and Management of COVID-19: Antiviral Treatment for Mild to Moderate COVID-19 in Adults

Sign in to react

Enter your email and we send a 6-digit code and a link. No password.

Your name and role

These appear beside any methods concern you post and on your profile page.